volume 28, issue 2, P241-281 2012
DOI: 10.3233/jad-2011-110986
View full text
|
Sign up to set email alerts
|
Share

Abstract: Therapeutic options for Alzheimer's disease are currently limited to symptomatic treatment that only provides modest and temporary maintenance of cognitive and memory functions, without altering disease progression. Although a variety of therapeutics targeting amyloid production or plaque degradation as well as tau hyperphosphorylation and aggregation have been proposed, examined in pre-clinical models and introduced into clinical trials, many have failed to provide significant therapeutic benefit. Concerns ov…

Expand abstract

Search citation statements

Order By: Relevance

Citation Types

0
37
0
1

Paper Sections

0
0
0
0
0

Publication Types

0
0
0
0

Relationship

0
0

Authors

Journals